Eli Lilly and Company (NYSE:LLY) Shares Bought by Advisor OS LLC

Advisor OS LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 51.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,039 shares of the company's stock after acquiring an additional 1,377 shares during the quarter. Advisor OS LLC's holdings in Eli Lilly and Company were worth $2,355,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. Lipe & Dalton acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $26,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the third quarter valued at $36,000. St. Johns Investment Management Company LLC lifted its stake in Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company's stock worth $39,000 after acquiring an additional 37 shares in the last quarter. Family CFO Inc acquired a new stake in Eli Lilly and Company during the 3rd quarter worth about $40,000. Finally, O Brien Wealth Partners LLC grew its stake in Eli Lilly and Company by 70.5% during the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company's stock valued at $44,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on LLY shares. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an "outperform" rating in a report on Wednesday, May 1st. Bank of America upped their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. Truist Financial lifted their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the company a "buy" rating in a research report on Wednesday, May 1st. Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 7th. Finally, Wells Fargo & Company lifted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an "overweight" rating in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $757.95.

Eli Lilly and Company Price Performance

Shares of LLY traded down $11.55 during trading hours on Friday, hitting $760.00. The stock had a trading volume of 2,082,289 shares, compared to its average volume of 2,926,412. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78. The stock has a market capitalization of $722.31 billion, a price-to-earnings ratio of 111.93, a P/E/G ratio of 1.50 and a beta of 0.37. The company's fifty day moving average is $761.48 and its two-hundred day moving average is $678.11. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company's revenue was up 26.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.62 EPS. On average, analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company's dividend payout ratio is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.